Description: Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases in the United States. Its lead product candidate is CM-101, a humanized monoclonal antibody attenuates the basic function of CCL24 that is in phase 2 clinical trial for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.
Home Page: www.chemomab.com
Building 7
Tel Aviv,
6158002
Israel
Phone:
972 77 331 0156
Officers
Name | Title |
---|---|
Dr. Adi Mor George Ph.D. | Co-Founder, Chief Scientific Officer, CEO & Executive Director |
Ms. Sigal Fattal CPA, M.B.A. | Chief Financial Officer |
Dr. Matthew B. Frankel M.B.A., M.D. | Chief Medical Officer & VP of Drug Development |
Barbara Lindheim | Consulting Vice President of Investor & Public Relations, Strategic Communications |
Mr. Jack Lawler | Senior VP of Global Clinical Development Operations |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
Forward PE: | 0 |
---|---|
Trailing PE: | 0 |
Price-to-Book MRQ: | 1.7981 |
Price-to-Sales TTM: | 0 |
IPO Date: | |
Fiscal Year End: | December |
Full Time Employees: | 0 |